Literature DB >> 35821476

Bioluminescent and Fluorescent Reporter-Expressing Recombinant SARS-CoV-2.

Desarey Morales Vasquez1, Kevin Chiem1, Chengjin Ye1, Luis Martinez-Sobrido2,3.   

Abstract

Reporter-expressing recombinant severe acute respiratory syndrome coronavirus 2 (rSARS-CoV-2) represents an excellent tool to understand the biology of and ease studying viral infections in vitro and in vivo. The broad range of applications of reporter-expressing recombinant viruses is due to the facilitated expression of fluorescence or bioluminescence readouts. In this chapter, we describe a detailed protocol on the generation of rSARS-CoV-2 expressing Venus, mCherry, and NLuc that represents a valid surrogate to track viral infections.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Bioluminescence (BL); Coronavirus; Coronavirus disease 2019 (COVID-19); Fluorescence (FL); NanoLuc (NLuc); Recombinant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Reporter genes; Reporter virus; Venus; mCherry

Mesh:

Year:  2022        PMID: 35821476     DOI: 10.1007/978-1-0716-2453-1_18

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  39 in total

1.  COVID antibody treatments show promise for preventing severe disease.

Authors:  Heidi Ledford
Journal:  Nature       Date:  2021-03       Impact factor: 49.962

2.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.

Authors:  Danuta M Skowronski; Gaston De Serres
Journal:  N Engl J Med       Date:  2021-02-17       Impact factor: 91.245

3.  The coding capacity of SARS-CoV-2.

Authors:  Yaara Finkel; Orel Mizrahi; Aharon Nachshon; Shira Weingarten-Gabbay; David Morgenstern; Yfat Yahalom-Ronen; Hadas Tamir; Hagit Achdout; Dana Stein; Ofir Israeli; Adi Beth-Din; Sharon Melamed; Shay Weiss; Tomer Israely; Nir Paran; Michal Schwartz; Noam Stern-Ginossar
Journal:  Nature       Date:  2020-09-09       Impact factor: 49.962

Review 4.  Mechanisms of coronavirus cell entry mediated by the viral spike protein.

Authors:  Sandrine Belouzard; Jean K Millet; Beth N Licitra; Gary R Whittaker
Journal:  Viruses       Date:  2012-06-20       Impact factor: 5.048

5.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors:  Chaolin Huang; Yeming Wang; Xingwang Li; Lili Ren; Jianping Zhao; Yi Hu; Li Zhang; Guohui Fan; Jiuyang Xu; Xiaoying Gu; Zhenshun Cheng; Ting Yu; Jiaan Xia; Yuan Wei; Wenjuan Wu; Xuelei Xie; Wen Yin; Hui Li; Min Liu; Yan Xiao; Hong Gao; Li Guo; Jungang Xie; Guangfa Wang; Rongmeng Jiang; Zhancheng Gao; Qi Jin; Jianwei Wang; Bin Cao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

6.  The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine - United States, December 2020.

Authors:  Sara E Oliver; Julia W Gargano; Mona Marin; Megan Wallace; Kathryn G Curran; Mary Chamberland; Nancy McClung; Doug Campos-Outcalt; Rebecca L Morgan; Sarah Mbaeyi; José R Romero; H Keipp Talbot; Grace M Lee; Beth P Bell; Kathleen Dooling
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2020-12-18       Impact factor: 17.586

Review 7.  SARS-CoV-2 variants, spike mutations and immune escape.

Authors:  William T Harvey; Alessandro M Carabelli; Ben Jackson; Ravindra K Gupta; Emma C Thomson; Ewan M Harrison; Catherine Ludden; Richard Reeve; Andrew Rambaut; Sharon J Peacock; David L Robertson
Journal:  Nat Rev Microbiol       Date:  2021-06-01       Impact factor: 78.297

8.  Dating first cases of COVID-19.

Authors:  David L Roberts; Jeremy S Rossman; Ivan Jarić
Journal:  PLoS Pathog       Date:  2021-06-24       Impact factor: 6.823

9.  Emergent Inpatient Administration of Casirivimab and Imdevimab Antibody Cocktail for the Treatment of COVID-19 Pneumonia.

Authors:  Alexander T Phan; Janet Gukasyan; Sarkis Arabian; Sharon Wang; Michael M Neeki
Journal:  Cureus       Date:  2021-05-27

Review 10.  An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future.

Authors:  Marco Tuccori; Irma Convertino; Sara Ferraro; Giulia Valdiserra; Emiliano Cappello; Elisabetta Fini; Daniele Focosi
Journal:  Expert Opin Drug Discov       Date:  2021-07-30       Impact factor: 6.098

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.